Related Experiment Video

Updated: Jul 7, 2026

A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease
05:39

A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease

Published on: June 13, 2025

Alzheimer's disease and mild cognitive impairment deteriorate fine movement control

Jin H Yan1, Susan Rountree, Paul Massman

  • 1Department of Kinesiology, California State University at East Bay, 25800 Carlos Bee Boulevard, Hayward, CA 94542-3062, USA. jin.yan@csueastbay.edu

Journal of Psychiatric Research
|February 19, 2008
PubMed

Insights

Fine motor control deficits, including slower and less coordinated handwriting, are key indicators of sensory-motor dysfunction in Alzheimer's disease (AD) and mild cognitive impairment (MCI). These findings highlight handwriting analysis as a potential diagnostic tool for early AD and MCI detection.

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Sensory-motor dysfunctions are frequently observed in individuals with Alzheimer's disease (AD) and mild cognitive impairment (MCI).
  • Deterioration in fine motor control and coordination may represent a significant aspect of these sensory-motor deficits.

Purpose of the Study:

  • To investigate fine motor control and coordination deficits in handwriting among patients with AD, MCI, and healthy controls.
  • To determine if handwriting kinematic profiles can differentiate between these groups.

Main Methods:

  • Nine probable AD patients, nine amnestic MCI subjects, and ten healthy controls performed four handwriting movements on a digitizer.
  • Analysis focused on movement time, smoothness, and kinematic profiles.
  • Group comparisons were made across movement types and between subject groups.

Main Results:

  • Patients with AD and MCI exhibited significantly slower, less smooth, and less coordinated handwriting movements compared to healthy controls.
  • Movement consistency was also reduced in the AD and MCI groups.
  • Distinct kinematic profiles were observed between the patient groups and the control group.

Conclusions:

  • Fine motor deficits, particularly in handwriting, are characteristic of sensory-motor impairments in AD and MCI.
  • Handwriting analysis offers a practical and potentially valuable method for assessing sensory-motor system deterioration in AD and MCI.
  • These findings underscore the relevance of fine motor tasks in understanding the neurodegenerative processes of AD and MCI.

More Related Videos

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...